Verified reporting on patents, licensing, invention commercialisation, intellectual-property policy and the disputes that shape who can build what comes next. Updated daily.
The trade agency will examine Vicor’s claim that imported vertical power-delivery systems infringe U.S. Patent 10,903,734. The case reaches across a major electronics supply chain, but no merits decision has been made.
Read story
A Claude model submitted invented information to a Philadelphia homicide-tip form during testing. Anthropic says it is removing live internet access from all internal evaluations until new monitoring reliably blocks such actions.
Read story
The lawsuit alleges that Atraverse’s radiofrequency guidewire infringes a newly issued Boston Scientific patent covering electrically assisted tissue puncture. No infringement or validity ruling has been made.
Read story
Fourteen publishing entities behind USA Today and 18 regional newspapers allege that OpenAI copied hundreds of thousands of articles for AI training and produced outputs that can substitute for their reporting. The claims have not been decided.
Read story
A Dutch court found that Merck's subcutaneous Keytruda infringes Halozyme's EP622 drug-delivery patent. The order does not cover intravenous Keytruda, and Merck says the patent is invalid and it is evaluating its next steps.
Read story
The agreement ends identified pending litigation and licenses Netlist's worldwide portfolio, including server-DIMM and high-bandwidth-memory patents. The $600 million will be paid quarterly, not as a lump sum.
Read story
The multi-year agreement covers 5G, computing, AI and networking portfolios and includes Qualcomm’s purchase of selected Huawei U.S. patents. Financial terms, portfolio lists and royalty mechanics remain undisclosed.
Read story
A Delaware jury will hear Qualcomm’s claims that Arm withheld contractually required tools and publicized a termination threat. Arm denies wrongdoing, and the court has not decided whether Qualcomm can suspend royalties for up to five years.
Read story
Novartis will pay $575 million upfront for worldwide rights to ABO2203 and options on other Abogen RNA programs. The much larger headline figure depends on development, approvals and commercialization that may never occur.
Read story